Pendopharm Announces Public Coverage for Octasa® (Oral Mesalamine) in Canada

Overview of Octasa® (Oral Mesalamine)

Pendopharm, a division of Pharmascience Inc., has taken a significant step forward in the accessibility of treatment for patients suffering from inflammatory bowel disease. The company has announced that Octasa® 800 mg and Octasa® 1600 mg will now be publicly covered in most Canadian provinces.

Importance of Public Coverage

This public coverage enables broader access to effective treatments, allowing healthcare providers to prescribe Octasa® as a standard option. Patients will benefit from reduced out-of-pocket expenses, making medication affordable and accessible.

Details About Octasa®

• Octasa® is a formulation of oral mesalamine used in managing ulcerative colitis and other inflammatory bowel diseases.
• The new coverage applies to both 800 mg and 1600 mg dosages, enhancing treatment compliance and outcomes.
• Patients should consult their healthcare providers for more information about how this coverage can benefit their treatment plans.

Conclusion of Announcement

This pivotal move by Pendopharm underscores the company's commitment to improving healthcare access and patient welfare. It reflects ongoing efforts to ensure patients with inflammatory bowel disease receive necessary treatments through public healthcare initiatives.